Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

ClinicalTrials.gov ID: NCT00040027

Public ClinicalTrials.gov record NCT00040027. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver failure or liver cancer. The current treatment for hepatitis C infection in previously untreated patients is successful in only about half of patients. There is no established therapy for non-responders. This is a randomized, double-blinded, multicenter trial to determine the effectiveness of thymosin alpha 1 (thymalfasin) 1.6 mg twice weekly plus PEGinterferon alfa-2a 180 ug/wk compared to placebo plus PEGinterferon alfa-2a in adults with chronic hepatitis C without cirrhosis who are non-responders to previous treatment with interferon or interferon plus ribavirin. The definition of non-response requires a positive HCV RNA test at the end of a course of at least 12 weeks of therapy. Patients will receive treatment for 12 months, and will be followed-up for a further 6 months after the end of therapy.

Study identification

NCT ID
NCT00040027
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
SciClone Pharmaceuticals
Industry
Enrollment
500 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2002
Primary completion
Not listed
Completion
Not listed
Last update posted
Jan 14, 2008

Started 2002

United States locations

U.S. sites
46
U.S. states
25
U.S. cities
39
Facility City State ZIP Site status
University of Alabama - Knollwood Physician's Group Bldg. Mobile Alabama
Mayo Clinic Scottsdale Arizona
Gastroenterology Associates of East Bay Medical Group Berkeley California
Scripps Clinic La Jolla California
Cedars-Sinai Medical Center Los Angeles California
California Pacific Medical Center San Francisco California
Veterans Administration Medical Center GI Section (111B) San Francisco California
Walter Reed Army Medical Center Washington D.C. District of Columbia
Washington Hospital Center Washington D.C. District of Columbia
University of Florida Gainesville Florida
Mayo Clinic Jacksonville Florida
University of Miami Center for Liver Diseases Miami Florida
Atlanta Gastroenterology Associates Atlanta Georgia
Center for Digestive and Liver Health Savannah Georgia
Idaho Gastroenterology Associates Meridian Idaho
University of Chicago Hospital & Clinic Chicago Illinois
Hepatitis C Treatment Centers, Inc. Louisville Kentucky
Liver Research Center - University of Louisville Louisville Kentucky
Louisiana State University Healthcare Network New Orleans Louisiana
Johns Hopkins University Baltimore Maryland
Chevy Chase Clinical Research Chevy Chase Maryland
New England Medical Center Boston Massachusetts
University of Massachusetts Memorial Medical Center Worcester Massachusetts
William Beaumont Hospital Royal Oak Michigan
Mississippi Gastrointestinal Associates Jackson Mississippi
VAMC Kansas City Missouri
Saint Louis University Hospital St Louis Missouri
North Shore University Hospital Manhasset New York
Bronx VA Medical Center New York New York
NY VAMC New York New York
NYU Hospitals Center New York New York
Carolinas Center for Liver Diseases Charlotte North Carolina
Duke University Medical Center Durham North Carolina
University of Cincinnati - College of Medicine Cincinnati Ohio
Metro Health Medical Center, GI Division Cleveland Ohio
Oregon Health Sciences University Portland Oregon
University of Pennsylvania Hospital Philadelphia Pennsylvania
Roger Williams Medical Center Providence Rhode Island
GI Center MidSouth Memphis Tennessee
University of Tennessee Gastroenterology Memphis Tennessee
Baylor University Medical Center Dallas Texas
University of Texas Southwestern Medical Center Dallas Texas
Baylor, VAMC Houston Texas
Metropolitan Research Fairfax Virginia
McGuire Research Institute Richmond Virginia
Wisconsin Center for Advanced Research Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00040027, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 14, 2008 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00040027 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →